WuXi Biologics (Cayman) Inc. (2269.HK) — Financial ratios
Profitability, liquidity, leverage, and valuation ratios for WuXi Biologics (Cayman) Inc., with annual and quarterly history.
| Metric | 2025 |
|---|---|
| Valuation | |
| P/E Ratio | 23.73x |
| P/B Ratio | 2.53x |
| P/S Ratio | 5.48x |
| Profitability | |
| Gross Margin | 46.0% |
| Operating Margin | 30.5% |
| Net Margin | 22.5% |
| EBITDA Margin | 36.4% |
| Liquidity | |
| Current Ratio | 3.14x |
| Quick Ratio | 2.97x |
| Leverage | |
| Debt/Equity | 0.07x |
YoY = year-over-year change. Source: FMP..